Physician profile
Len A Brown
NPI 1245293364
$4,755.44
in general payments reported to CMS, 2019-2025
23 companies · $649 in 2025
The $649 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $341 · 2021: $955 · 2022: $643 · 2023: $714 · 2024: $950 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,306 · Education: $7.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,305.78 |
| Education | $7.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,100.20 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Coopervision INC. | $632.40 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Dompe US, INC. | $347.40 | 2021-2024 | Oxervate |
| Biotissue Holdings INC. | $328.28 | 2024-2025 | |
| Johnson & Johnson Vision Care, INC. | $262.74 | 2020-2025 | Acuvue |
| Horizon Therapeutics Plc | $248.70 | 2021-2022 | |
| Alcon Vision LLC | $220.54 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $215.88 | 2019-2020 | |
| Maculogix, INC. | $183.14 | 2019-2020 | |
| Optos, INC. | $116.74 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $114.59 | 2021 | |
| Sun Pharmaceutical Industries INC. | $113.31 | 2021 | |
| Aerie Pharmaceuticals, INC. | $113.14 | 2021 | |
| Sight Sciences, INC. | $100.38 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.35 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $99.93 | 2025 | Xdemvy |
| Abbvie INC. | $99.54 | 2023-2024 | Durysta |
| Ocular Therapeutix, INC. | $91.51 | 2022 | |
| Optovue, INC. | $90.34 | 2019 | |
| Amgen INC. | $84.48 | 2024 | Tepezza |
| Astellas Pharma US INC | $50.97 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $23.98 | 2021 | |
| Rayner Intraocular Lenses Limited | $16.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Len Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.